Alexandra L Hernandez1, Rajiv Karthik, Murugesan Sivasubramanian, Anantharam Raghavendran, Manu Gnanamony, Shelly Lensing, Jeannette Y Lee, Rajesh Kannangai, Priya Abraham, Dilip Mathai, Joel M Palefsky. 1. *Department of Medicine, University of California, San Francisco, CA; †School of Public Health, Department of Epidemiology, University of California, Berkeley, CA; ‡Department of Medicine, Christian Medical College, Vellore, India; §The Humsafar Trust, Mumbai, India; ‖Department of Clinical Virology, Christian Medical College, Vellore, India; ¶Department of Cancer Biology and Pharmacology, University of Illinois, Chicago, IL; #Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and **Apollo Institute of Medical Sciences and Research, Hyderabad, India.
Abstract
BACKGROUND: India has a large population of HIV-positive individuals, including men who have sex with men (MSM), and the incidence of human papillomavirus (HPV)-related cancers is high. In developed countries, HIV-positive MSM exhibit the highest prevalence of anal HPV infection and incidence of anal cancer. Little is known about anal HPV infection in HIV-positive Indian MSM. METHODS: We evaluated 300 HIV-positive MSM from 2 cities in India. Men were tested for anal HPV infection using L1-HPV DNA polymerase chain reaction with probes specific for 29 types and a mixture of 10 additional types. CD4 level and plasma HIV viral load were measured. Participants completed an interviewer-administered questionnaire including a sexual history. RESULTS: The prevalence of anal HPV was 95% (95% confidence interval: 91% to 97%). The 3 most common types were HPV 35 (20%), HPV 16 (13%), and HPV 6/11 (13%). History of taking antiretroviral medications decreased risk of anal HPV 16 infection [relative risk (RR): 0.6 (0.4-1.0)]. Having an increased number of vaginal sex partners lowered risk of any anal HPV infection. Ever having receptive sex increased risk of any anal HPV [RR: 1.2 (1.1-1.4)] and anal HPV 16 [RR: 6.5 (1.8-107)]. CONCLUSIONS: Almost all Indian HIV-positive MSM had anal HPV infection. The prevalence of HPV 16 was lower and the prevalence of other oncogenic HPV types was higher than in similar populations in North America and Europe. Vaccine-based prevention strategies for HPV infection in India should consider potential differences in HPV type distribution among HIV-infected MSM when designing interventions.
BACKGROUND: India has a large population of HIV-positive individuals, including men who have sex with men (MSM), and the incidence of human papillomavirus (HPV)-related cancers is high. In developed countries, HIV-positive MSM exhibit the highest prevalence of anal HPV infection and incidence of anal cancer. Little is known about anal HPV infection in HIV-positive Indian MSM. METHODS: We evaluated 300 HIV-positive MSM from 2 cities in India. Men were tested for anal HPV infection using L1-HPV DNA polymerase chain reaction with probes specific for 29 types and a mixture of 10 additional types. CD4 level and plasma HIV viral load were measured. Participants completed an interviewer-administered questionnaire including a sexual history. RESULTS: The prevalence of anal HPV was 95% (95% confidence interval: 91% to 97%). The 3 most common types were HPV 35 (20%), HPV 16 (13%), and HPV 6/11 (13%). History of taking antiretroviral medications decreased risk of anal HPV 16infection [relative risk (RR): 0.6 (0.4-1.0)]. Having an increased number of vaginal sex partners lowered risk of any anal HPV infection. Ever having receptive sex increased risk of any anal HPV [RR: 1.2 (1.1-1.4)] and anal HPV 16 [RR: 6.5 (1.8-107)]. CONCLUSIONS: Almost all Indian HIV-positive MSM had anal HPV infection. The prevalence of HPV 16 was lower and the prevalence of other oncogenic HPV types was higher than in similar populations in North America and Europe. Vaccine-based prevention strategies for HPV infection in India should consider potential differences in HPV type distribution among HIV-infected MSM when designing interventions.
Authors: Sunil Suhas Solomon; Aylur K Srikrishnan; Frangiscos Sifakis; Shruti H Mehta; Canjeevaram K Vasudevan; Pachamuthu Balakrishnan; Kenneth H Mayer; Suniti Solomon; David D Celentano Journal: AIDS Behav Date: 2010-10
Authors: Alan G Nyitray; Roberto J Carvalho da Silva; Maria Luiza Baggio; Beibei Lu; Danélle Smith; Martha Abrahamsen; Mary Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: J Infect Dis Date: 2011-01-01 Impact factor: 5.226
Authors: Alexandra de Pokomandy; Danielle Rouleau; George Ghattas; Sylvie Vézina; Pierre Coté; John Macleod; Guy Allaire; Eduardo L Franco; François Coutlée Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: Aruna Alahari Dhir; Sheela Sawant; Rajesh P Dikshit; Purvish Parikh; Shyam Srivastava; Rajan Badwe; Sunil Rajadhyaksha; K A Dinshaw Journal: Cancer Causes Control Date: 2007-11-09 Impact factor: 2.506
Authors: Nicolas Van de Velde; Marie-Claude Boily; Mélanie Drolet; Eduardo L Franco; Marie-Hélène Mayrand; Erich V Kliewer; François Coutlée; Jean-François Laprise; Talía Malagón; Marc Brisson Journal: J Natl Cancer Inst Date: 2012-10-27 Impact factor: 13.506
Authors: J J Rodrigues; S M Mehendale; M E Shepherd; A D Divekar; R R Gangakhedkar; T C Quinn; R S Paranjape; A R Risbud; R S Brookmeyer; D A Gadkari Journal: BMJ Date: 1995-07-29
Authors: Perry N Halkitis; Pamela Valera; Caleb E LoSchiavo; Stephen E Goldstone; Maria Kanztanou; Anthony J Maiolatesi; Danielle C Ompad; Richard E Greene; Farzana Kapadia Journal: AIDS Patient Care STDS Date: 2019-04 Impact factor: 5.078
Authors: Jessica A Kahn; Marvin Belzer; Xiaofei Chi; Jeannette Lee; Aditya H Gaur; Kenneth Mayer; Jaime Martinez; Donna C Futterman; Elizabeth A Stier; Mary E Paul; Elizabeth Y Chiao; Daniel Reirden; Steven E Goldstone; Ana P Ortiz Martinez; Edward R Cachay; Luis F Barroso; Maria Da Costa; Craig M Wilson; Joel M Palefsky Journal: Papillomavirus Res Date: 2019-01-15